MARKET

NXTS

NXTS

Nexentis Technologies Inc
NASDAQ
5.09
+0.19
+3.88%
Opening 12:04 05/28 EDT
OPEN
4.750
PREV CLOSE
4.900
HIGH
5.14
LOW
4.750
VOLUME
6.84K
TURNOVER
--
52 WEEK HIGH
89.79
52 WEEK LOW
3.380
MARKET CAP
3.72M
P/E (TTM)
-0.2057
1D
5D
1M
3M
1Y
5Y
1D
Nexentis Expands Credit Facility Under Amended Financing Agreement
TipRanks · 19h ago
Nexentis amends L.I.A. Pure Capital facility, raising credit line to EUR 10 million
PUBT · 19h ago
Weekly Report: what happened at NXTS last week (0518-0522)?
Weekly Report · 3d ago
Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone
TipRanks · 05/18 13:36
Nexentis Subsidiary MitoCareX Hits First Drug‑Discovery Milestone With Optimized Molecule
Benzinga · 05/18 13:33
Nexentis unit MitoCareX Bio generates optimized hit molecule for cancer, inflammation program
PUBT · 05/18 13:30
NEXENTIS ANNOUNCES MITOCAREX BIO ACHIEVES KEY R&D MILESTONE, GENERATING A SUBSTANTIALLY IMPROVED HIT MOLECULE ON THE PATH TO PRE-CLINICAL DEVELOPMENT
Reuters · 05/18 13:30
Weekly Report: what happened at NXTS last week (0511-0515)?
Weekly Report · 05/18 09:41
More
About NXTS
Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity.

Webull offers Nexentis Technologies Inc stock information, including NASDAQ: NXTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTS stock methods without spending real money on the virtual paper trading platform.